<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hartrampf PE</submitter><funding>Universitätsklinikum Würzburg</funding><funding>Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg</funding><pagination>4262-4270</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9525362</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>49(12)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Radioligand therapy (RLT) with &lt;sup>177&lt;/sup>Lu-labeled prostate-specific membrane antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with advanced, metastatic castration-resistant prostate cancer (mCRPC). A substantial number of patients, however, are prone to treatment failure. We aimed to determine clinical baseline characteristics to predict OS in patients receiving [&lt;sup>177&lt;/sup>Lu]Lu-PSMA I&amp;T RLT in a long-term follow-up.&lt;h4>Materials and methods&lt;/h4>Ninety-two mCRPC patients treated with [&lt;sup>177&lt;/sup>Lu]Lu-PSMA I&amp;T with a follow-up of at least 18 months were retrospectively identified. Multivariable Cox regression analyses were performed for various baseline characteristics, including laboratory values, Gleason score, age, pri</pubmed_abstract><journal>European journal of nuclear medicine and molecular imaging</journal><pubmed_title>Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [&lt;sup>177&lt;/sup>Lu]Lu-PSMA I&amp;T during long-term follow-up.</pubmed_title><pmcid>PMC9525362</pmcid><funding_grant_id>Z-02/85</funding_grant_id><pubmed_authors>Seitz AK</pubmed_authors><pubmed_authors>Kubler H</pubmed_authors><pubmed_authors>Weinzierl FX</pubmed_authors><pubmed_authors>Schirbel A</pubmed_authors><pubmed_authors>Rowe SP</pubmed_authors><pubmed_authors>Buck AK</pubmed_authors><pubmed_authors>Serfling SE</pubmed_authors><pubmed_authors>Hartrampf PE</pubmed_authors><pubmed_authors>Werner RA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [&lt;sup>177&lt;/sup>Lu]Lu-PSMA I&amp;T during long-term follow-up.</name><description>&lt;h4>Background&lt;/h4>Radioligand therapy (RLT) with &lt;sup>177&lt;/sup>Lu-labeled prostate-specific membrane antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with advanced, metastatic castration-resistant prostate cancer (mCRPC). A substantial number of patients, however, are prone to treatment failure. We aimed to determine clinical baseline characteristics to predict OS in patients receiving [&lt;sup>177&lt;/sup>Lu]Lu-PSMA I&amp;T RLT in a long-term follow-up.&lt;h4>Materials and methods&lt;/h4>Ninety-two mCRPC patients treated with [&lt;sup>177&lt;/sup>Lu]Lu-PSMA I&amp;T with a follow-up of at least 18 months were retrospectively identified. Multivariable Cox regression analyses were performed for various baseline characteristics, including laboratory values, Gleason score, age, pri</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-22T09:38:58.06Z</modification><creation>2024-11-15T00:42:20.898Z</creation></dates><accession>S-EPMC9525362</accession><cross_references><pubmed>35650263</pubmed><doi>10.1007/s00259-022-05853-2</doi></cross_references></HashMap>